£1,304.95 – £3,894.95

European Due Diligence Summit for Life Sciences (EXL)

Event Information

Share this event

Date and Time



Radisson Blu Portman Hotel, London

22 Portman Square



United Kingdom

View Map

Refund Policy

Refund Policy

No Refunds

Friends Who Are Going
Event description


European Due Diligence Summit for Life Sciences

Recent years have shown a rise in development across the generic and biosimilar industries, as many blockbuster products near the end of their patents. The need to expand the reach of R&D programmes has driven major new investments in co-development, strategic alliances, licensing and acquisitions, with big pharmaceutical companies scrambling to maintain their strongholds in specific therapeutic areas. This has increased the need for a robust due diligence process across all functions, as companies look to external targets as a means of supplementing pipelines and bolstering their product portfolios.

With the rising costs of drug and device reviews and the uncertainty of FDA approvals, the prospect of developing a new product from discovery onward has become a highly risky endeavour. Therefore, conducting strategic due diligence to identify and integrate potential targets at a stage of assured success, though costly, can often be an efficient approach to supplement organic business development.

Over the last four years, ExL Events’ US-based conference has provided due diligence professionals with a platform to explore innovative models and deal structures for collaborating with strategic partners, and discussed valuable strategies for conducting efficient and effective due diligence. Join your peers at the inaugural European Due Diligence Summit for Life Sciences for the opportunity to network and engage with some of the industry’s leading experts.

Top Five Reasons to Attend

  1. Explore best practices for companies of all sizes looking to acquire or in-license a product
  2. Understand how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal
  3. Learn how to evaluate and effectively manage strategic alliances through case studies from industry leaders
  4. Assess the regulatory and compliance standards of a target and how gaps can lead to unforeseen financial burdens
  5. Gain valuable insight on the impact company culture can have on the success of integrating the workforce post-merger or acquisition

Who Should Attend

This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:

  • Due Diligence
  • Business Development
  • Strategic Alliance/Alliance Management
  • Mergers and Acquisitions
  • Licensing
  • Intellectual Property and Patent Counsel
  • Search and Evaluation
  • Portfolio Management
  • Scientific Assessment
  • General Counsel/Corporate Counsel
  • Legal and Regulatory Compliance
  • Regulatory Affairs
  • Research and Development
  • Clinical Medicine
  • Clinical Operations
  • Lifecycle Management

This conference is also of interest to:

  • Investment Banks
  • Private Equity Firms
  • Venture Capitalists
  • Data Room Providers
  • Due Diligence Consultants
  • Law Firms
  • Clinical Affairs and CRO Partners
  • Regulatory Affairs and Compliance Partners


Mike Myers,
Senior Director, Lilly Research Labs — Due Diligence,



Gareth Ayre,
Head Centre of Excellence, Due Diligence,

NOVARTISCristiano Musso,
Chief Business Officer,

CIRCASSIARoland Pfeiffer, Ph.D.,
Head, Commercial Development Europe,

Executive Director, Diligence,

Head, External Innovation and Licensing,



Day 1

Monday, 26 February 2018

8:00 – 8:45
Registration and Continental Breakfast

8:45 – 9:00
Chairperson’s Opening Remarks

Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY

9:00 – 9:45
Guidelines for Developing an Efficient and Targeted Due Diligence Plan

Chris Davie, Executive Director, Diligence, MUNDIPHARMA

9:45 – 10:30
Centre of Excellence: An Organisational Model for Driving Continuous Improvement in Due Diligence Practice

Gareth Ayre, Head Centre of Excellence, Due Diligence, NOVARTIS

10:30 – 11:00
Networking Break

11:00 – 11:45
Best Practice in Developing a Focused Intellectual Property Due Diligence Process

Steven Gurney, Principal Associate and Patent Attorney, MARKS & CLERK
Will James, Partner and Solicitor, MARKS & CLERK

11:45 – 12:30
Valuation Approaches for Licencing and M&A Transactions in the Life Science Industry

12:30 – 13:30

13:30 – 14:15
Identify Negotiation Factors That Can Impact the Purchase Price and Deal Structure of a Transaction

14:15 – 15:00
PANEL: Understand How to Make a Deal More Attractive to Investors

Lubor Gaal, Ph.D., Head of External Innovation and Licensing, ALMIRALL
Austin Doyle, Ph.D., FRSB, Director, Science and Technology Licensing, R&D Worldwide Business Development, GSK
Carl Jessop, FRQA, Due Diligence Director, Business Development, ASTRAZENECA

15:00 – 15:30
Networking Break

15:30 – 16:15
Partnerships, Prioritisation and Diligence

Nick Clarke, Ph.D., Head of U.K. Academic Partnerships, External Science and Innovation, PFIZER

16:15 – 17:00
Interactive Learning Discussion: Discover How Your Peers Conduct Due Diligence at Their Organisations

Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY

17:00 –
Day One Concludes

Day 2

Tuesday, 27 February 2018

8:00 – 9:00
Continental Breakfast

9:00 – 9:15
Chairperson’s Recap of Day One

Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY

9:15 – 9:45
Successfully Run a Gap Analysis to Determine the Development Costs and Future Sales for an EarlyStage Asset

Marco Cerato, Head of BD&L, Late-Stage and Marketed Products, HELSINN

9:45 – 10:30
Case Study: Considerations for Selecting a Marketing or Promotion Partner That Is Right For Your Product

Roland Pfeiffer, Ph.D., Head Commercial Development Europe, VIFOR PHARMA

10:30 – 11:00
Networking Break

11:00 – 11:45
Virtual Due Diligence and How to Successfully Leverage Data Rooms

John Easton, Ph.D., Head of Business Operations, Business Development, ASTRAZENECA

11:45 – 12:30
Panel: Effective Strategies for Working With External Advisors and Consultants

Cristiano Musso, Chief Business Officer, CIRCASSIA

12:30 – 13:15

13:15 – 14:00
Integration Management: The Challenge of Avoiding Value Deprivation of a Deal Post-Due Diligence

Robert Bauer, Ph.D., Director, Business Development EMEA, SANTEN

14:00 – 14:45
Case Study: Recognising and Challenging Bias in Navigating Portfolio Decision-Making

Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY

14:45 – 15:00
Chairperson’s Closing Remarks

15:00 –
Conference Concludes

Event Partners






Technology Networks

Share with friends

Date and Time


Radisson Blu Portman Hotel, London

22 Portman Square



United Kingdom

View Map

Refund Policy

No Refunds

Save This Event

Event Saved